Romania Depression Therapeutics Market Analysis

Romania Depression Therapeutics Market Analysis


$ 3999

Romania's depression therapeutics market is expected to grow from $29 Mn in 2022 to $45 Mn in 2030 with a CAGR of 5.45% for the forecasted year 2022-30. The introduction of new and ground-breaking medicines for the treatment of depression and increased healthcare funding in Romania has resulted in the expansion of the market. The Romania depression therapeutics market is segmented by drug type, therapies, indication, and end users. Oftafarma, Zentiva, and Bristol-Myers Squibb are the major players in the Romania depression therapeutics market.

ID: IN10ROPH034 CATEGORY: Pharmaceuticals GEOGRAPHY: Romania AUTHOR: Dr. Parul Choudhary

Buy Now

Romania Depression Therapeutics Market Executive Analysis

Romania's depression therapeutics market is expected to grow from $29 Mn in 2022 to $45 Mn in 2030 with a CAGR of 5.45% for the forecasted year 2022-30. The government of Romania announced on Thursday that it is putting forth a draft budget for 2023 based on estimates of a deficit of roughly 4.4% of gross domestic product (GDP) and a 2.8% increase in the economy. After Poland, Romania had the second-largest pharmaceutical market in terms of revenue in 2021 with $4.36 Bn. Pharmaceutical distribution has continued to be the most valuable business segment over the past ten years, followed by pharmacies and production. Pharmaceutical distribution accounted for 68% of the pharmaceutical industry's total income in Romania, which is estimated to have reached $15 Bn in 2022.

According to estimates, 1018 new instances of depression are reported annually per 100,000 people in Romania, making up about 1% of the population. There were 166,594 individuals registered with different types of mental disorders in 2003, including 28,895 children. 8.6% of them were institutionalized.

There are presently significant limitations to the therapeutic management of depression, and this low efficacy is reflected in the high rates of non-response even after numerous antidepressant trials in Romania. Nearly two-thirds of patients with severe depression who tried an antidepressant for 4-6 weeks did not experience remission, and more than 30% of these patients are thought to be treatment-resistant. Although significant resources have been devoted to the study of neurobiologically oriented Major Depressive Disorder (MDD) treatments, the FDA has only authorized a small number of products that do not fit the monoamine hypothesis' conceptual framework. Brexanolone for postpartum depression and ketamine for MDD that is resistant to therapy are two exceptions to this rule. However, a variety of pathogenetic pathways have been researched, from glutamatergic, opioidergic, or sestrin modulators to abnormalities in orexinergic or -aminobutyric acid (GABA) neurotransmission. New triple monoaminergic inhibitors and new atypical antipsychotics are two examples of the new generation of monoaminergic agents that have been investigated. In an effort to find novel ways to reduce lingering symptoms or increase the likelihood that treatment-resistant MDD patients will respond or experience remission, old medications have been repurposed as antidepressants or adjuvants to current antidepressant therapy.

Romania Depression Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

One of the major trends in psychopharmacology and depression has been an exponential rise in the number of medications accessible in Romania for the treatment of mental disorders. Anti-depressant drugs take the lead in this diverse environment because depression continues to be one of the most serious public health issues in Romania, with a lifetime incidence of 20–35% and significant costs to both the person and the community. With an emphasis on enhancing access to healthcare services, Romania has recently increased its healthcare spending. As a result of increased treatment options and better access to care, the Romania depression therapeutics market is expanding.

Market Restraints

Despite the real benefits, side effects like vertigo and activation are possible with all serotonin selective reuptake inhibitors (SSRIs). On the other hand, these effects tend to stabilize over time. (sedation, sexual side effects). Additionally, some patients are dubious about the real impact of SSRIs due to their ambivalent effects, at least in terms of mood parameters [e.g., sedation (paroxetine, fluvoxamine) vs. activation (fluoxetine, sertraline)] thus limiting the growth of the Romania depression therapeutics market. Despite the advancements made by the pharmaceutical industry in recent decades, there is presently no antidepressant that can be regarded as being tailored to the majority of patients who need antidepressant medication. While some patients may become non-compliant, for others, the benefits may outweigh the dangers (which could expose them to drug abuse, with consequences like tolerance and psychological addiction). These problems could severely hamper the development of the Romania depression therapeutics market.

Competitive Landscape

Key Players

  • Biotehnos (ROU)
  • Rontis (ROU)
  • Fiterman Pharma (ROU)
  • Oftafarma (ROU)
  • Zentiva (ROU)
  • Bristol-Myers Squibb
  • GSK
  • Bayer
  • Lupin
  • Perrigo
  • Johnson & Johnson
  • Sun Pharmaceutical
  • Amneal Pharmaceuticals

Notable Events

March 2022- The Depression Scorecard was introduced to stakeholders by the Janssen Pharmaceutical Companies of Johnson & Johnson. It is a report that suggests a number of suggested actions to enhance the administration and care of patients with depression in Romania. Johnson & Johnson Pharmaceutical Companies sponsored and spearheaded the drafting of the document. The article builds on a 2018 European Union study by nine stakeholder groups, which identified ten areas that require urgent attention if "A Sustainable Approach to Depression: Moving from Words to Action" is to be achieved.

Healthcare Policies and Regulatory Landscape

The residents of Romania have access to a public healthcare system that offers them fundamental medical treatment. The Romanian government offers some coverage for mental health services through its public healthcare system, including compensation plans for treating depression. However, there are often extended waiting lists for appointments with mental health professionals and inadequate access to mental health services. In Romania, there are also private health insurance options, but they are less prevalent due to their expensive premiums and negligible coverage of mental health services. Counselling and psychotherapy are covered by some private brokers, though the coverage may be limited and come with high copays and deductibles.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Depression Therapeutics Segmentation

By Drug Type (Revenue, USD Billion):

  • Antidepressants
  • Anxiolytics
  • Anticonvulsants
  • Noradrenergic Agents
  • Atypical Antipsychotics

By Therapies (Revenue, USD Billion):

  • Electroconvulsive Therapy (ECT)
  • Cognitive Behaviour Therapy (CBT)
  • Psychotherapy
  • Deep Brain Stimulation
  • Transcranial Magnetic Stimulation (TMS)
  • Cranial electrotherapy stimulation (CES)

By Indication (Revenue, USD Billion):

  • Major Depressive Disorder (MDD)
  • Bipolar Disorder
  • Dysthymic Disorder
  • Postpartum Depression
  • Seasonal Affective Disorder (SAD)
  • Premenstrual Dysphoric Disorder (PMDD)
  • Others

By End Users (Revenue, USD Billion):

  • NGOs
  • Asylums
  • Hospitals
  • Mental Healthcare Centers

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Oftafarma, Zentiva, and Bristol-Myers Squibb are the major players in the Romania depression therapeutics market.

The Romania depression therapeutics market is expected to grow from $29 Mn in 2022 to $45 Mn in 2030 with a CAGR of 5.45% for the forecasted year 2022-2030.

The Romania depression therapeutics market is segmented by drug type, therapies, indication, and by end users.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 16 January 2024
Updated by: Vidhi Upadhyay

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up